NNRTI and other class resistance in treatment-naïve patients in North America and Western Europe [12,13].

<p>NNRTI and other class resistance in treatment-naïve patients in North America and Western Europe [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072784#B12" target="_blank">12</a>,<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072784#B13" target="_blank">13</a>].</p

Mean monthly per patient healthcare costs of US patients on ART from 1996 to 1998 [65].

<p>Mean monthly per patient healthcare costs of US patients on ART from 1996 to 1998 [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072784#B65" target="_blank">65</a>].</p

Mean per-patient healthcare costs for patients on increasing lines of treatment in US [63] and Europe [54].

<p>Mean per-patient healthcare costs for patients on increasing lines of treatment in US [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072784#B63" target="_blank">63</a>] and Europe [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072784#B54" target="_blank">54</a>].</p

US total healthcare costs of patients with HIV.

<p>Note: Right axis: mean per patient costs in 2000 [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072784#B57" target="_blank">57</a>] and 2006 [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072784#B58" target="_blank">58</a>]; Left axis: proportion of total healthcare costs due to hospitalizations and ARV drugs.</p

Reported prevalence of 1^st-generation NNRTI resistance in the US and European countries among treatment-naïve patients.

<p>Note: Solid and dotted lines indicate trend lines for Europe and US, respectively. References available from the author.</p

Demographic and Clinical Characteristics, by Cohort.

<p>IQR, interquartile range; SD, standard deviation.</p>a<p>Other health plan includes basic/major medical, exclusive provider organization, consumer-directed health plan, and high-deductible health plan.</p

Kaplan-Meier estimate of time to first treatment switch.

<p>Kaplan-Meier estimate of time to first treatment switch.</p

Proportion of total cost by component and treatment line in the Newly Treated Cohort.

<p>ARV, antiretroviral; ER, emergency room.</p

Patient selection: (A) Newly Treated Cohort; (B) CD4 Measurements Cohort.

<p>ARV, antiretroviral.</p